BenzingaAugust 18, 2026 at 1:06 AM NY17 days ago
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Jim Cramer Thinks This Struggling Stock Could See A “Big Earnings Acceleration”
Yahoo4 hours ago
Walmart, Target, and Kroger face growing retail crime issue
Yahoo4 hours ago
Cramer Says a Wave of 21 Year Olds on Robinhood Is the Only Reason This Market Has Not Cracked
Yahoo6 hours ago
Top Research Reports for Apple, Broadcom & Shell
Yahoo7 hours ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo7 hours ago